Johnson & Johnson (JNJ) Revenue by Segment
Johnson & Johnson revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 28, 2026), Johnson & Johnson's largest business segment was Innovative Medicine, with $16.38 billion or 65% of revenue, up 7.8% from a year earlier. Next: MedTech (35%).
By product or service, Darzalex brought in 17%, Tremfya brought in 8% and General brought in 6% of revenue in Q2 fiscal 2026.
By region, United States brought in 57%, Europe brought in 23% and Asia-Pacific, Africa brought in 15% of revenue in Q2 fiscal 2026.
The fastest-growing business segment from a year earlier was Innovative Medicine (+7.8%).
From company filings, in USD; latest quarter ended June 28, 2026; quarterly data from Q1 fiscal 2017.
Johnson & Johnson
Revenue breakdown
Fiscal quarters, from company filings
Johnson & Johnson revenue by business segment, last 4 quarters
| Business segment | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Innovative Medicine | $16.4B | $15.4B | $15.6B | $15.2B | 65% |
| MedTech | $8.9B | $8.6B | $8.4B | $8.5B | 35% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Johnson & Johnson revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Darzalex | $4.2B | $4.0B | $3.7B | $3.5B | 17% |
| Tremfya | $2.0B | $1.6B | $1.4B | $1.2B | 8% |
| General | $1.5B | $1.4B | $1.4B | $1.4B | 6% |
| United States | $1.4B | $1.4B | $1.3B | $1.4B | 6% |
| Advanced | $1.2B | $1.1B | $1.2B | $1.2B | 5% |
| Contact Lenses/Other | $1.0B | $969.0M | $1.0B | $965.0M | 4% |
| Invega Sustenna/Xeplion/Trinza/Trevicta | $1.0B | $1.0B | $929.0M | $992.0M | 4% |
| Erleada | $995.0M | $949.0M | $936.0M | $908.0M | 4% |
| Non-US | $978.0M | $978.0M | $908.0M | $947.0M | 4% |
| Trauma | $827.0M | $833.0M | $793.0M | $768.0M | 3% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Johnson & Johnson revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $14.5B | $13.3B | $13.7B | $13.5B | 57% |
| Europe | $5.7B | $5.8B | $5.4B | $5.4B | 23% |
| Asia-Pacific, Africa | $3.7B | $3.6B | $3.6B | $3.6B | 15% |
| Western Hemisphere, excluding U.S. | $1.3B | $1.3B | $1.2B | $1.2B | 5% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
What are Johnson & Johnson's business segments?
Innovative Medicine and MedTech (as reported for Q2 fiscal 2026).
Which business segment makes the most money for Johnson & Johnson?
Innovative Medicine: $16.38 billion, or 65% of revenue, in Q2 fiscal 2026.
What are Johnson & Johnson's main products and services?
By revenue in Q2 fiscal 2026: Darzalex (17%), Tremfya (8%), General (6%) and United States (6%).
Where does Johnson & Johnson make its money?
By region in Q2 fiscal 2026: United States (57%), Europe (23%), Asia-Pacific, Africa (15%) and Western Hemisphere, excluding U.S. (5%).
